

Endoscopic Patient Clustering to Investigate Differential Treatment Effects of Guselkumab and Ustekinumab in Crohn's Disease: Post hoc Analysis of GALAXI and GRAVITI Trials

Dylan Richards¹, Loqmane Seridi¹, Klebea Sohn¹, Brad Mcrae¹, Nat Terry¹, Marion Vetter¹, Daniel Cua¹, Patrick Branigan¹, Walter Reinisch², Raja Atreya³

¹Janssen Research & Development, LLC, Spring House, PA, USA; ²Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria; ³Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

Key Takeaways

✓ Data-driven endoscopic patient clustering in Crohn's disease can lead to stratified understanding of differential treatment effects between guselkumab (GUS) and ustekinumab (UST)

✓ In addition to overall WK48 endoscopic superiority, endoscopic clustering indicated higher WK12 endoscopic remission with GUS than UST in ~40% of patients

✓ Improved narrowing characterized a subset of GUS responders at WK12, and not UST, highlighting potential role of GUS in affecting stricture biology for future mechanistic research

Background

Guselkumab (GUS), a selective IL-23p19 subunit inhibitor, demonstrated statistical superiority in endoscopic endpoints to ustekinumab (UST), an IL-23/IL-12p40 subunit inhibitor, by end of maintenance treatment in patients with moderately to severely active Crohn's disease (CD) in the Phase 2/3 GALAXI studies.¹

Differences in endoscopic response and biological features across ileum- and colon-involved Crohn's disease (CD) suggest distinct mechanisms for healing.²

Objectives


Understanding endoscopic heterogeneity (i.e., degree of involvement in each segment) across patients may help to delineate treatment effect differences between GUS and UST

Methods

Endoscopic clustering was established using baseline segment Simple Endoscopic Score for CD (SES-CD) values from terminal ileum, right colon, transverse colon, left/sigmoid colon, and rectum from cohort 1 (1233 patients, GALAXI 1, GALAXI 2, GRAVITI trials) and cohort 2 (525 patients, GALAXI 3).

Patient clusters were identified using consensus hierarchical clustering, and a machine learning classification model was developed for patient cluster assignment of cohort 2.

GALAXI 2 and GALAXI 3 patients were combined to evaluate Week (WK) 12 and WK48 endoscopic outcomes between PBO, GUS, and UST.








Data-driven endoscopic patient clustering using segmental SESCD. Segment SESCD: sum of 4 subscores (0-3): size of ulcers, percent ulcerated surface, percent affected surface, presence of narrowing (stenosis/structuring)

Results

Data-driven endoscopic clustering identified 7 CD subtypes, highlighting heterogeneity within ileocolonic and colonic standard classifications

Guselkumab showed higher WK12 endoscopic remission rates than ustekinumab in 38% of patients followed by higher rates overall by WK48

Improved narrowing at WK12 contributes to endoscopic response with guselkumab, but not with ustekinumab, in patients with stricturing CD



The identified subtypes were used to stratify endoscopic remission rates along with additional clinical features, such as segmental narrowing scores, to identify consolidated groups with differential treatment effects

- GUS shows early WK12 endoscopic remission for all patients
- Endoscopic characterization indicates UST having placebo-like efficacy at WK12 in 38% of patients, including Group 2, characterized by the "Ileum only" subtype and Group 3, consisting largely of "Right colon dominant" and "Colonic" subtypes with impassable right colon narrowing scores
- GUS shows higher endoscopic remission than UST in all patients at WK48

Endoscopic response at WK12 for GUS and UST was also characterized by greater decreases in the other endoscopic subscores (i.e., percent affected, ulcer size, percent ulcerated surface) compared to non-responders (data not shown)